Can you explain ceftriaxone (Cetrikast), including its dosage, administration route, side effects, and precautions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ceftriaxone (Cetrikast): Medication Overview

Ceftriaxone is a third-generation cephalosporin antibiotic administered intravenously or intramuscularly, typically dosed once daily due to its long half-life, and is highly effective against a broad spectrum of bacterial infections including meningitis, urinary tract infections, respiratory infections, and gonorrhea.

What is Ceftriaxone?

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with enhanced activity against Gram-negative bacteria compared to earlier generation cephalosporins 1. It has a uniquely long half-life (5.4-10.9 hours) that allows for convenient once-daily dosing in most clinical situations 2.

Standard Dosing

Adults

  • Typical infections: 1-2 grams IV/IM once daily (or divided twice daily)
  • Maximum daily dose: 4 grams
  • Meningitis: 2 grams IV every 12 hours (empiric therapy) 3
  • Uncomplicated gonorrhea: Single 250 mg IM dose 1
  • Surgical prophylaxis: Single 1 gram IV dose 30 minutes to 2 hours before surgery 1

Pediatric Patients

  • Skin/soft tissue infections: 50-75 mg/kg once daily (max 2 grams) 1
  • Acute otitis media: Single 50 mg/kg IM dose (max 1 gram) 1
  • Serious infections (non-meningitis): 50-75 mg/kg daily divided every 12 hours (max 2 grams) 1
  • Meningitis: Initial dose 100 mg/kg (max 4 grams), then 100 mg/kg/day once daily or divided every 12 hours for 7-14 days 4, 1

Neonates (Critical Precautions)

Ceftriaxone is contraindicated in premature neonates and in any neonate ≤28 days requiring calcium-containing IV solutions 1. When used in term neonates:

  • Administer IV doses over 60 minutes (not 30 minutes) to reduce bilirubin encephalopathy risk 1
  • For infants 22-60 days old with fever: 50 mg/kg IV/IM once daily 4
  • Never use in hyperbilirubinemic neonates 1

Administration Routes

Intravenous (IV)

  • Infuse over 30 minutes in adults and children 1
  • Infuse over 60 minutes in neonates 1
  • Concentrations between 10-40 mg/mL are recommended 1
  • Compatible diluents: sterile water, 0.9% sodium chloride, 5% dextrose 1

Intramuscular (IM)

  • Inject deep into large muscle mass 1
  • Reconstitute to 250 mg/mL or 350 mg/mL concentration 1
  • Can use 1% lidocaine (without epinephrine) as diluent for IM injection 1

Common Side Effects

Based on safety data from 2,640 patients 5:

  • Gastrointestinal effects (3.45%): Diarrhea most common
  • Hypersensitivity reactions (2.99%): Rash, pruritus
  • Local reactions (1.86%): Pain at injection site, phlebitis (more common with twice-daily dosing)
  • Laboratory abnormalities: Elevated liver transaminases (10% of patients) 6

Serious Adverse Effects (Rare but Important)

  • Anaphylaxis: Rare but possible 4
  • Immune hemolytic anemia: Can cause acute hemolysis with 24% mortality in historical cases (though declining to 18% in recent reports); requires immediate discontinuation 7
  • Bilirubin encephalopathy: Risk in neonates, especially with rapid infusion 1
  • Ceftriaxone-calcium precipitation: Fatal cases reported when mixed with calcium-containing solutions 1

Critical Precautions and Contraindications

Absolute Contraindications

  1. Premature neonates (any gestational age) 1
  2. Neonates ≤28 days requiring calcium-containing IV solutions 1
  3. Hyperbilirubinemic neonates 1

Drug Incompatibilities

Never mix or administer simultaneously with 1:

  • Calcium-containing solutions (Ringer's, Hartmann's solution)
  • Vancomycin (give sequentially with line flush between)
  • Aminoglycosides (give sequentially with line flush between)
  • Fluconazole (give sequentially with line flush between)
  • Amsacrine (give sequentially with line flush between)

Special Populations

  • Pregnancy: Safe to use; avoid quinolones and tetracyclines instead 8
  • Renal/hepatic impairment: No dose adjustment needed unless severe combined impairment 1
  • Elderly: No dose adjustment needed up to 2 grams daily if no severe organ dysfunction 1

Duration of Therapy

  • Most infections: Continue for at least 2 days after clinical improvement; typical duration 4-14 days 1
  • Streptococcus pyogenes infections: Minimum 10 days 1
  • Meningitis: 7-14 days depending on organism and clinical response 4, 1
  • Gonorrhea: Single dose 1

Clinical Efficacy

Ceftriaxone demonstrates 93% clinical response rates across various infections 6 and 94% bacteriological eradication of susceptible pathogens 6. Once-daily dosing is as effective as twice-daily dosing for most infections 9, 10, 2, with the exception that empiric meningitis treatment may benefit from twice-daily dosing initially 11, 12.

For bacterial meningitis in children, recent pharmacokinetic modeling suggests 100 mg/kg once daily achieves better CSF target attainment (88% PTA) compared to 50 mg/kg twice daily (53% PTA) at 24 hours 11, though both achieve 100% probability of target attainment at steady state.

Storage and Stability

  • Store powder at 20-25°C (68-77°F), protected from light 1
  • Once reconstituted, solutions remain stable:
    • Room temperature (25°C): 2 days for most diluents 1
    • Refrigerated (4°C): 10 days for most diluents 1
  • Color ranges from light yellow to amber (normal) 1

Key Clinical Pearls

  • The long half-life allows once-daily dosing, improving convenience and potentially reducing IV line complications 9, 2
  • Achieves therapeutic levels in CSF, making it excellent for meningitis 6
  • No activity against Chlamydia trachomatis; add appropriate coverage if suspected 1
  • Limited activity against Pseudomonas aeruginosa; not recommended as sole therapy for pseudomonal infections 2
  • Mortality from ceftriaxone-associated hemolytic anemia has declined from 80% (1991-2000) to 18% (recent reports), likely due to earlier recognition 7

References

Research

Clinical adverse effects during ceftriaxone therapy.

The American journal of medicine, 1984

Research

Clinical evaluation of ceftriaxone.

Clinical therapeutics, 1984

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.